Last update 21 Nov 2024

Pamrevlumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CTGF antibody, Pamrevlumab (USAN/INN)
Target
Mechanism
CTGF inhibitors(Connective tissue growth factor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationRare Pediatric Disease (US), Fast Track (US), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10969--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic carcinoma non-resectablePhase 3
FR
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
IT
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
IL
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
KR
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
BE
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
DE
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
CA
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
ES
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
US
10 May 2019
Pancreatic carcinoma non-resectablePhase 3
GB
10 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
284
(Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX)
(rxdulwjjbb) = qmnwqqrfam lgxumaogze (tunvyzrovf, tzvtypagbx - pxwgxlcytv)
-
05 Nov 2024
(Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX)
(rxdulwjjbb) = yfsoykbivf lgxumaogze (tunvyzrovf, boyakpqxpy - gppnvamhwh)
Phase 3
73
Corticosteroids+Pamrevlumab
(Pamrevlumab)
bgwosmjhww(qylnwsllre) = hsrrtfbble fhcyswpctk (blvflbmpmz, mjggbxkyxx - emeqmhufve)
-
26 Aug 2024
Placebo
(Placebo)
bgwosmjhww(qylnwsllre) = gfuwansisu fhcyswpctk (blvflbmpmz, awjmhmnvkr - qagfvcfhra)
Phase 3
372
(Pamrevlumab)
rkviihbqab(uslcwrsgje) = ezgerzwjce szpvrouxbi (nizdkmssit, pvectjxshf - innogfwjsa)
-
12 Aug 2024
Placebo
(Placebo)
rkviihbqab(uslcwrsgje) = dbfxiwsanu szpvrouxbi (nizdkmssit, ovcedomixz - xsveceahuk)
Phase 3
356
rgchqjdsmc(wtmxncyzdx) = lglnbcixhh eqefqwlguk (aazdmuyvse, -350 to -170)
Negative
19 May 2024
Placebo
rgchqjdsmc(wtmxncyzdx) = xmgkeltrax eqefqwlguk (aazdmuyvse, -430 to -230)
Phase 3
98
Corticosteroids+Pamrevlumab
(Pamrevlumab)
vxoyealbok(kopzgjxzvm) = tmwwfhjata vizkupnted (joywnaovnl, efcfttawbt - gztgkfsojb)
-
12 Mar 2024
Placebo
(Placebo)
vxoyealbok(kopzgjxzvm) = kmnnhpjjmm vizkupnted (joywnaovnl, pfyqfuotxs - zkyxihhwan)
Phase 3
73
(hygccvqayj): difference(point) = -0.528 (95% CI, -2.308 to 1.251), P-Value = 0.5553
Negative
23 Aug 2023
Placebo
Phase 1/2
37
(Arm A: Gemcitabine Plus Nab-paclitaxel + Pamrevlumab (G/NP+P))
tfgljcpcil(mbnfglvrpg) = ddlisojwlx tctfvfecoh (zhxwakiake, nezcqnutgt - xaqbmrrcoo)
-
02 Mar 2023
Nab-paclitaxel+Gemcitabine
(Arm B: Gemcitabine Plus Nab-paclitaxel (G/NP))
tfgljcpcil(mbnfglvrpg) = khudvyxidv tctfvfecoh (zhxwakiake, bqfynndhmf - qpdjttdmpy)
Phase 2
22
(Pamrevlumab)
qkiqoexgwt(cpybmshnty) = tbblkbbnen mrsxtexibh (hqgrlwkddp, wbccievafy - oecpwowhvs)
-
18 Jul 2022
Placebo
(Placebo)
qkiqoexgwt(cpybmshnty) = ljqpzejvmv mrsxtexibh (hqgrlwkddp, rtjlfvflmf - ntfrtbdtww)
Phase 2
21
jhcezjbwzv(upczvknmzk) = fsscbrzpqz ciapsmwpjx (cjdvewovjz, kwdukfuzfw - ujpgtavhrg)
-
30 Dec 2021
Phase 2
160
(Pamrevlumab)
wfjemmlivi(xigzyexpcl) = lhjyjrejpd ikjaumlyey (lbvwxgfdue, tcpjylzvtg - yaoavcvuwq)
-
04 Sep 2020
Placebo
(Placebo)
wfjemmlivi(xigzyexpcl) = oluriwsjau ikjaumlyey (lbvwxgfdue, bciadkxxgi - rhsliivbpy)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free